A20 attenuates allergic airway inflammation in mice

Journal of Immunology

Volumn 183, Issue 2, 2009, Pages 1488-1495

  Kang, Nam In ^a   Yoon, Ha Yong ^a   Lee, Young Rae ^a   Won, Minho ^a   Chung, Myoung Ja ^a   Park, Jin Woo ^a   Hur, Gang Min ^b   Lee, Hern Ku ^a   Park, Byung Hyun ^a  

^a Chonbuk National University   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIALLERGIC AGENT; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OVALBUMIN; PROTEIN A20; UNCLASSIFIED DRUG; CYSTEINE PROTEINASE; CYTOKINE; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, MOUSE;

AIRWAY HYPERRESPONSIVENESS; ALLERGIC AIRWAY INFLAMMATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; LUNG LAVAGE; MOUSE; MUCUS SECRETION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT DISEASE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; ADENOVIRUS; ANIMAL; BIOSYNTHESIS; BRONCHUS HYPERREACTIVITY; GENE VECTOR; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY;

ADENOVIRIDAE; ANIMALS; BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE FLUID; CYSTEINE ENDOPEPTIDASES; CYTOKINES; GENETIC VECTORS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NF-KAPPA B; OVALBUMIN; SIGNAL TRANSDUCTION;

EID: 70249117539     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900163     Document Type: Article

References (50)

1. 2 activity in a murine asthma model. Clin. Exp. Allergy 38: 357-364.
2. Matsuda, A., K. Orihara, S. Fukuda, H. Fujinaga, K. Matsumoto, and H. Saito. 2008. Corticosteroid enhances TNF-α-mediated leukocyte adhesion to pulmonary microvascular endothelial cells. Allergy 63: 1610-1616.
3. Alves Rde, S., A. Vianna Fde, and C. A. Pereira. 2008. Clinical phenotypes of severe asthma. J. Brasil Pneumol. 34: 646-653.
4. Moore, W. C., and S. P. Peters. 2006. Severe asthma: an overview. J. Allergy Clin. Immunol. 117: 487-494.
5. Silvestri, M., M. Bontempelli, M. Giacomelli, M. Malerba, G. A. Rossi, A. Di Stefano, A. Rossi, and F. L. Ricciardolo. 2006. High serum levels of tumour necrosis factor-α and interleukin-8 in severe asthma: markers of systemic inflammation? Clin. Exp. Allergy 36: 1373-1381. (Pubitemid 44674121)
6. Tillie-Leblond, I., P. Gosset, and A. B. Tonnel. 2005. Inflammatory events in severe acute asthma. Allergy 60: 23-29.
7. Kamath, A. V., I. D. Pavord, P. R. Ruparelia, and E. R. Chilvers. 2005. Is the neutrophil the key effector cell in severe asthma? Thorax 60: 529-530.
8. Louis, R., and R. Djukanovic. 2006. Is the neutrophil a worthy target in severe asthma and chronic obstructive pulmonary disease? Clin. Exp. Allergy 36: 563-567.
9. Holgate, S. T. 2006. A need for circulating biomarkers of severe persistent asthma and its treatment. Clin. Exp. Allergy 36: 1355-1356.
10. Holgate, S. T., J. Holloway, S. Wilson, P. H. Howarth, H. M. Haitchi, S. Babu, and D. E. Davies. 2006. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J. Allergy Clin. Immunol. 117: 496-506.
11. Feldmann, M., F. M. Brennan, B. M. Foxwell, P. C. Taylor, R. O. Williams, and R. N. Maini. 2005. Anti-TNF therapy: where have we got to in 2005? J. Autoimmun. 25 Suppl: 26-28.
12. Deveci, F., M. H. Muz, N. Ilhan, G. Kirkil, T. Turgut, and N. Akpolat. 2008. Evaluation of the anti-inflammatory effect of infliximab in a mouse model of acute asthma. Respirology 13: 488-497.
13. Edwards, C. J., and R. Polosa. 2007. Study of infliximab treatment in asthma. Am. J. Respir. Crit. Care Med. 175: 196.
14. Antoniu, S. A. 2006. Etanercept for refractory asthma therapy. Expert Opin. Invest. Drugs 15: 1279-1281.
15. Morjaria, J. B., A. J. Chauhan, K. S. Babu, R. Polosa, D. E. Davies, and S. T. Holgate. 2008. The role of a soluble TNFα receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 63: 584-591.
16. Baert, F., M. De Vos, E. Louis, and S. Vermeire. 2007. Immunogenicity of infliximab: how to handle the problem? Acta Gastroenterol. Belg. 70: 163-170. (Pubitemid 47066267)
17. Hanauer, S. B. 2003. Immunogenicity of infliximab in Crohn's disease. N. Engl. J. Med. 348: 2155-2156.
18. Fonollosa, A., A. Segura, J. Giralt, and J. Garcia-Arumi. 2007. Tuberculous uveitis after treatment with etanercept. Graefes Arch Clin. Exp. Ophthalmol. 245: 1397-1399.
19. Gonzalez-Lopez, M. A., R. Blanco, M. C. Gonzalez-Vela, H. Fernandez-Llaca, and V. Rodriguez-Valverde. 2006. Development of sarcoidosis during etanercept therapy. Arthritis Rheum. 55: 817-820.
20. Canas, C. A., G. J. Tobon, L. G. Arango, and N. Guarin. 2009. Developing of granulomatous thyroiditis during etanercept therapy. Clin. Rheumatol. 28: S17-S19.
21. Dempsey, P. W., S. E. Doyle, J. Q. He, and G. Cheng. 2003. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev. 14: 193-209.
22. Heyninck, K., and R. Beyaert. 2005. A20 inhibits NF-κB activation by dual ubiquitin-editing functions. Trends Biochem. Sci. 30: 1-4.
23. Sheikh, M. S., and Y. Huang. 2003. Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle 2: 550-552.
24. Coornaert, B., I. Carpentier, and R. Beyaert. 2009. A20: Central gatekeeper in inflammation and immunity. J. Biol. Chem. 284: 8217-8221.
25. Grey, S. T., M. B. Arvelo, W. Hasenkamp, F. H. Bach, and C. Ferran. 1999. A20 inhibits cytokine-induced apoptosis and nuclear factor κB-dependent gene activation in islets. J. Exp. Med. 190: 1135-1146.
26. Li, H. L., M. L. Zhuo, D. Wang, A. B. Wang, H. Cai, L. H. Sun, Q. Yang, Y. Huang, Y. S. Wei, P. P. Liu, et al. 2007. Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 115: 1885-1894.
27. Lee, J. H., M. Y. Song, E. K. Song, E. K. Kim, W. S. Moon, M. K. Han, J. W. Park, K. B. Kwon, and B. H. Park. 2009. Overexpression of SIRT1 protects pancreatic β-cells against cytokine toxicity by suppressing the nuclear factor-κB signaling pathway. Diabetes 58: 344-351.
28. Kim, Y. S., H. M. Ko, N. I. Kang, C. H. Song, X. Zhang, W. C. Chung, J. H. Kim, I. H. Choi, Y. M. Park, G. Y. Kim, et al. 2007. Mast cells play a key role in the development of late airway hyperresponsiveness through TNF-α in a murine model of asthma. Eur. J. Immunol. 37: 1107-1115.
29. Choi, I. W., Y. S. Kim, D. K. Kim, J. H. Choi, K. H. Seo, S. Y. Im, K. S. Kwon, M. S. Lee, T. Y. Ha, and H. K. Lee. 2003. Platelet-activating factor-mediated NF-κB dependency of a late anaphylactic reaction. J. Exp. Med. 198: 145-151.
30. Blease, K., A. Lewis, and H. K. Raymon. 2003. Emerging treatments for asthma. Expert Opin. Emerg. Drugs 8: 71-81.
31. Brightling, C., M. Berry, and Y. Amrani. 2008. Targeting TNF-α: a novel therapeutic approach for asthma. J. Allergy Clin. Immunol. 121: 5-10.
32. Heffler, E., M. Berry, and I. D. Pavord. 2007. Tumor necrosis factor-α: a promising therapeutic target for asthma? BioDrugs 21: 345-349.
33. Evans, C. M., K. Kim, M. J. Tuvim, and B. F. Dickey. 2009. Mucus hypersecretion in asthma: causes and effects. Curr. Opin. Pulm. Med. 15: 4-11.
34. Nakae, S., L. H. Ho, M. Yu, R. Monteforte, M. Iikura, H. Suto, and S. J. Galli. 2007. Mast cell-derived TNF contributes to airway hyperreactivity, inflammation, and TH2 cytokine production in an asthma model in mice. J. Allergy Clin. Immunol. 120: 48-55.
35. Ginsberg, H. S., L. L. Moldawer, P. B. Sehgal, M. Redington, P. L. Kilian, R. M. Chanock, and G. A. Prince. 1991. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc. Natl. Acad. Sci. USA 88: 1651-1655.
36. Minter, R. M., J. E. Rectenwald, K. Fukuzuka, C. L. Tannahill, D. La Face, V. Tsai, I. Ahmed, E. Hutchins, R. Moyer, E. M. Copeland, 3rd, and L. L. Moldawer. 2000. TNF-α receptor signaling and IL-10 gene therapy regulate the innate and humoral immune responses to recombinant adenovirus in the lung. J. Immunol. 164: 443-451.
37. Elkon, K. B., C. C. Liu, J. G. Gall, J. Trevejo, M. W. Marino, K. A. Abrahamsen, X. Song, J. L. Zhou, L. J. Old, R. G. Crystal, and E. Falck-Pedersen. 1997. Tumor necrosis factor α plays a central role in immune-mediated clearance of adenoviral vectors. Proc. Natl. Acad. Sci. USA 94: 9814-9819.
38. Broide, D. H., M. Lotz, A. J. Cuomo, D. A. Coburn, E. C. Federman, and S. I. Wasserman. 1992. Cytokines in symptomatic asthma airways. J. Allergy Clin. Immunol. 89: 958-967.
39. Thomas, P. S., D. H. Yates, and P. J. Barnes. 1995. Tumor necrosis factor-α increases airway responsiveness and sputum neutrophilia in normal human subjects. Am. J. Respir. Crit. Care Med. 152: 76-80.
40. Wertz, I. E., K. M. O'Rourke, H. Zhou, M. Eby, L. Aravind, S. Seshagiri, P. Wu, C. Wiesmann, R. Baker, D. L. Boone, et al. 2004. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430: 694-699.
41. Song, H. Y., M. Rothe, and D. V. Goeddel. 1996. The tumor necrosis factorinducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-κB activation. Proc. Natl. Acad. Sci. USA 93: 6721-6725.
42. Boone, D. L., E. E. Turer, E. G. Lee, R. C. Ahmad, M. T. Wheeler, C. Tsui, P. Hurley, M. Chien, S. Chai, O. Hitotsumatsu, et al. 2004. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat. Immunol. 5: 1052-1060.
43. Zhang, S. Q., A. Kovalenko, G. Cantarella, and D. Wallach. 2000. Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKγ) upon receptor stimulation. Immunity 12: 301-311.
44. Idel, S., H. M. Dansky, and J. L. Breslow. 2003. A20, a regulator of NFκB, maps to an atherosclerosis locus and differs between parental sensitive C57BL/6J and resistant FVB/N strains. Proc. Natl. Acad. Sci. USA 100: 14235-14240.
45. Wolfrum, S., D. Teupser, M. Tan, K. Y. Chen, and J. L. Breslow. 2007. The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-κB target genes. Proc. Natl. Acad. Sci. USA 104: 18601-18606.
46. Herrick, C. A., and K. Bottomly. 2003. To respond or not to respond: T cells in allergic asthma. Nat. Rev. Immunol. 3: 405-412.
47. Li, L., Y. Xia, A. Nguyen, Y. H. Lai, L. Feng, T. R. Mosmann, and D. Lo. 1999. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J. Immunol. 162: 2477-2487.
48. Pennings, H. J., K. Kramer, A. Bast, W. A. Buurman, and E. F. Wouters. 1998. Tumor necrosis factor-α induces hyperreactivity in tracheal smooth muscle of the guinea-pig in vitro. Eur. Respir J. 12: 45-49.
49. Reynolds, A. M., M. D. Holmes, and R. Scicchitano. 2000. Cytokines enhance airway smooth muscle contractility in response to acetylcholine and neurokinin A. Respirology 5: 153-160.
50. Wills-Karp, M. 1999. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol. 17: 255-281. (Pubitemid 29241125)